Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 17/20 | 0.68 |
| ▸ | HTR2C | P28335 | 17/20 | 0.68 |
| ▸ | HTR2B | P41595 | 8/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.68 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.68 |
| ▸ | HTR1D | P28221 | 1/20 | 0.68 |
| ▸ | HTR7 | P34969 | 1/20 | 0.68 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.68 |
| ▸ | KMO | O15229 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10199642 | 1.00 | HTR2A (0.68) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| Fumaric Acid SCHEMBL8006854 | 0.89 | HTR2A (0.58) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| Fumaric Acid SCHEMBL8009273 | 0.89 | HTR2A (0.58) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| Fumaric Acid SCHEMBL8009278 | 0.89 | HTR2A (0.58) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL906040 | 0.85 | HTR2A (0.60) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL15713263 | 0.83 | HTR2A (0.47) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL10252671 | 0.82 | HTR2A (0.71) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL8007544 | 0.81 | HTR2C (0.69) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL4779282 | 0.81 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A | |
| SCHEMBL6088764 | 0.81 | HTR2A (1.00) | HTR2AHTR2CHTR2BHTR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000017170-A2 | N1-SUBSTITUTED BENZOPYRAZOLES AS INHIBITORS OF 5-HT2 RECEPTORS | VERNALIS RESEARCH LIMITED (GB) | 2000-03-30 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| CN-1780612-B | Treatment of incontinence with 5HT2C agonists. | PFIZER | 2010-12-01 | — | — | CN | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| CN-1780612-A | Treatment of incontinence with 5HT2C agonists. | PFIZER (US) | 2006-05-31 | — | — | CN | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.